National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer

Featured Clinical Trials

Cancer Studies Highlighted in the NCI Cancer Bulletin
< Back to Main

Related Pages
Search for Clinical Trials 1
NCI's PDQ® Cancer Clinical Trials Registry.

Pancreatic Cancer Home Page 2
NCI's gateway for information about pancreatic cancer.
Pancreatic Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

1.  Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors 5
(Posted: 11/03/2009) - In this clinical trial, patients who have solid tumors that cannot be removed by surgery or that have spread to other areas of the body will be treated with the PARP inhibitor AZD2281 and chemotherapy drugs cisplatin and gemcitabine.

2.  Immunotherapy for Advanced Pancreatic Cancer 6
(Posted: 04/25/2006, Updated: 06/13/2008) - In this trial, researchers are using a monoclonal antibody called MDX-010 to treat patients with advanced pancreatic cancer. MDX-010 binds to and blocks the activity of an immune response inhibitor molecule called CTLA-4.

3.  Adjuvant Biological Therapy for Pancreatic Cancer 7
(Posted: 10/10/2006, Updated: 01/15/2008) - In this trial, patients with completely resected pancreatic cancer will receive adjuvant chemotherapy and radiation therapy plus additional treatment with either bevacizumab or cetuximab, monoclonal antibodies that target different proteins important for cancer growth and spread.

4.  Gene Therapy for Metastatic Cancer 8
(Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients.

5.  Combination Therapy for Advanced Pancreatic Cancer 9
(Posted: 08/16/2005) - In this study, researchers are adding a biological agent called bevacizumab (Avastin®) to standard chemotherapy with the drug gemcitabine to see if the combination can help improve the survival of pancreatic cancer patients whose disease has spread to nearby lymph nodes or to other sites in the body.
1 2 10   Next > 10


Table of Links

1http://www.cancer.gov/clinicaltrials/search
2http://www.cancer.gov/cancertopics/types/pancreatic
3http://www.cancer.gov/clinicaltrials/ft-more-than-one-type
4http://www.cancer.gov/clinicaltrials/ft-supportive-care
5http://www.cancer.gov/clinicaltrials/ft-NCI-08-C-0128
6http://www.cancer.gov/clinicaltrials/ft-NCI-05-C-0141
7http://www.cancer.gov/clinicaltrials/ft-ECOG-E2204
8http://www.cancer.gov/clinicaltrials/ft-NCI-07-C-0003
9http://www.cancer.gov/clinicaltrials/ft-CALGB-80303
10http://www.cancer.gov/clinicaltrials/ft-pancreatic-cancer?keyword=pancreatic&st
artMonth=1&startYear=1961&endMonth=1&endYear=2108&page=2